190 related articles for article (PubMed ID: 28379600)
1. Hepatotoxicity associated to synthetic cannabinoids use.
Solimini R; Busardò FP; Rotolo MC; Ricci S; Mastrobattista L; Mortali C; Graziano S; Pellegrini M; di Luca NM; Palmi I
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(1 Suppl):1-6. PubMed ID: 28379600
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.
Tait RJ; Caldicott D; Mountain D; Hill SL; Lenton S
Clin Toxicol (Phila); 2016; 54(1):1-13. PubMed ID: 26567470
[TBL] [Abstract][Full Text] [Related]
3. Designer Drugs 2.0.
Huestis MA; Tyndale RF
Clin Pharmacol Ther; 2017 Feb; 101(2):152-157. PubMed ID: 28084644
[TBL] [Abstract][Full Text] [Related]
4. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.
Kassai S; Pintér JN; Rácz J; Böröndi B; Tóth-Karikó T; Kerekes K; Gyarmathy VA
Harm Reduct J; 2017 Feb; 14(1):9. PubMed ID: 28187774
[TBL] [Abstract][Full Text] [Related]
5. Next generation of novel psychoactive substances on the horizon - A complex problem to face.
Zawilska JB; Andrzejczak D
Drug Alcohol Depend; 2015 Dec; 157():1-17. PubMed ID: 26482089
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs of abuse: current perspectives on synthetic cannabinoids.
Debruyne D; Le Boisselier R
Subst Abuse Rehabil; 2015; 6():113-29. PubMed ID: 26543389
[TBL] [Abstract][Full Text] [Related]
7. "Legal Highs"--An Emerging Epidemic of Novel Psychoactive Substances.
Zawilska JB
Int Rev Neurobiol; 2015; 120():273-300. PubMed ID: 26070762
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Cannabinoids-Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis.
Fattore L
Biol Psychiatry; 2016 Apr; 79(7):539-48. PubMed ID: 26970364
[TBL] [Abstract][Full Text] [Related]
9. Synthetic cannabinoid use disorder: an update for general psychiatrists.
Grigg J; Manning V; Arunogiri S; Lubman DI
Australas Psychiatry; 2019 Jun; 27(3):279-283. PubMed ID: 30663326
[TBL] [Abstract][Full Text] [Related]
10. Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events.
Davidson C; Opacka-Juffry J; Arevalo-Martin A; Garcia-Ovejero D; Molina-Holgado E; Molina-Holgado F
Adv Pharmacol; 2017; 80():135-168. PubMed ID: 28826533
[TBL] [Abstract][Full Text] [Related]
11. Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes.
Kong TY; Kim JH; Kim DK; Lee HS
Arch Pharm Res; 2018 Jul; 41(7):691-710. PubMed ID: 30039377
[TBL] [Abstract][Full Text] [Related]
12. A New Differential Diagnosis: Synthetic Cannabinoids-Associated Acute Renal Failure.
Gudsoorkar VS; Perez JA
Methodist Debakey Cardiovasc J; 2015; 11(3):189-91. PubMed ID: 26634029
[TBL] [Abstract][Full Text] [Related]
13. Advances in urinary biomarker research of synthetic cannabinoids.
Wang Z; Leow EYQ; Moy HY; Chan ECY
Adv Clin Chem; 2023; 115():1-32. PubMed ID: 37673518
[TBL] [Abstract][Full Text] [Related]
14. Death cases involving certain new psychoactive substances: A review of the literature.
Kraemer M; Boehmer A; Madea B; Maas A
Forensic Sci Int; 2019 May; 298():186-267. PubMed ID: 30925344
[TBL] [Abstract][Full Text] [Related]
15. Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay.
Cannaert A; Storme J; Franz F; Auwärter V; Stove CP
Anal Chem; 2016 Dec; 88(23):11476-11485. PubMed ID: 27779402
[TBL] [Abstract][Full Text] [Related]
16. Impact of synthetic cannabinoids on the duration of opioid-related withdrawal and craving among patients of addiction clinics in Kazakhstan: A prospective case-control study.
Prilutskaya M; Bersani FS; Corazza O; Molchanov S
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631421
[TBL] [Abstract][Full Text] [Related]
17. [A review of side effects and complications with cannabinoid treatment].
Radbruch L; Nauck F
Schmerz; 2003 Aug; 17(4):274-9. PubMed ID: 12923677
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds.
Dresen S; Ferreirós N; Pütz M; Westphal F; Zimmermann R; Auwärter V
J Mass Spectrom; 2010 Oct; 45(10):1186-94. PubMed ID: 20857386
[TBL] [Abstract][Full Text] [Related]
19. Synthetic cannabinoids and their impact on neurodevelopmental processes.
Alexandre J; Carmo H; Carvalho F; Silva JP
Addict Biol; 2020 Mar; 25(2):e12824. PubMed ID: 31441196
[TBL] [Abstract][Full Text] [Related]
20. A Case of Status Epilepticus and Transient Stress Cardiomyopathy Associated with Smoking the Synthetic Psychoactive Cannabinoid, UR-144.
Al Fawaz S; Al Deeb M; Huffman JL; Al Kholaif NA; Garlich F; Chuang R
Am J Case Rep; 2019 Dec; 20():1902-1906. PubMed ID: 31857571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
